Circio Showcases Advancements in Circular RNA Technology at Industry Conferences

Circio Holding ASA has unveiled new data showcasing the transformative potential of its circular RNA (circRNA) circVec platform at two leading biopharma conferences in Switzerland and Sweden. CEO Dr. Erik Digman Wiklund and CSO Dr. Victor Levitsky presented findings demonstrating that circVec 3.0 significantly outperforms conventional mRNA-based technology, offering over 70 times greater RNA durability and 15 times enhanced protein expression. These breakthroughs strengthen the validation of Circio’s platform and its potential for next-generation nucleic acid medicine.

In vivo studies revealed that circVec exhibits a half-life of more than 600 hours, far exceeding the under-10-hour lifespan of linear mRNA. Additionally, novel lipid nanoparticle (LNP) delivery data showed strong and lasting circVec expression in the spleen, suggesting promising applications in cell and immune therapies. Dr. Levitsky highlighted the platform’s potential to transform AAV gene therapy, with further in vivo testing expected to yield results in the coming months. These advancements position Circio’s circVec technology as a game-changer in the field of genetic medicine, attracting growing interest from industry partners.